SCHEMBL133287

SCHEMBL133287

N[C@H](C(=O)O)C(=O)CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL133286 1.00
SCHEMBL27324011 0.77
Ethylene Glycol SCHEMBL14742401 0.75 PTGS1 (0.41)
SCHEMBL8731583 0.74
SCHEMBL22728604 0.74 LDHA (0.42)
SCHEMBL7208264 0.74
SCHEMBL14893046 0.74
SCHEMBL209221 0.73
Hydrochloric Acid SCHEMBL5422913 0.72 LDHA (0.40)
SCHEMBL28219859 0.72 LDHA (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1749031-B1 USE OF A scFv FOR DIMINISHING AN EXISTING BIOFILM HAPTOGEN LTD (GB) 2013-07-17 EP disclosed
US-20130045208-A1 Methods for the Treatment of an Infectious Bacterial Disease with an Anti-Lactone or Lactone Derived Signal Molecules Antibody Haptogen, Ltd. (GB) 2013-02-21 US disclosed
US-20130011400-A1 Methods For Inducing Autolysis In Infectious Bacteria HAPTOGEN LTD. (GB) 2013-01-10 US disclosed
US-8168397-B2 Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody HAPTOGEN LTD. (GB) 2012-05-01 US disclosed
EP-1528935-B1 METHODS FOR THE TREATMENT OF AN INFECTIOUS BACTERIAL DISEASE WITH AN ANTI-LACTONE OR LACTONE DERIVED SIGNAL MOLECULES ANTIBODY HAPTOGEN LTD (GB) 2012-03-21 EP disclosed
EP-1730197-B1 METHODS FOR INDUCING AUTOLYSIS IN INFECTIOUS BACTERIA HAPTOGEN LTD (GB) 2012-03-07 EP disclosed
EP-2281839-A2 Methods for reducing biofilm formation in infectious bacteria Haptogen Ltd (GB) 2011-02-09 EP disclosed
US-20110027280-A1 Methods For Inducing Autolysis In Infectious Bacteria HAPTOGEN LTD. (GB) 2011-02-03 US disclosed
EP-2261260-A2 Methods for inducing autolysis in infectious bacteria Haptogen Ltd (GB) 2010-12-15 EP disclosed
EP-2260868-A2 Methods for the treatment of an infectious bacterial disease with anti-lactone or lactone derived signal molecules antibody Haptogen Ltd (GB) 2010-12-15 EP disclosed
US-20090117109-A1 Methods For Reducing Biofilm Formation In Infectious Bacteria HAPTOGEN LTD. (GB) 2009-05-07 US disclosed
US-20070218058-A1 Methods For Inducing Autolysis In Infectious Bacteria HAPTOGEN LTD. POLWARTH BUILDING (GB) 2007-09-20 US disclosed
EP-1749031-A2 METHODS FOR REDUCING BIOFILM FORMATION IN INFECTIOUS BACTERIA Haptogen Ltd (GB) 2007-02-07 EP disclosed
EP-1730197-A2 METHODS FOR INDUCING AUTOLYSIS IN INFECTIOUS BACTERIA Haptogen Ltd (GB) 2006-12-13 EP disclosed
US-20060165704-A1 Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody HAPTOGEN LTD. (GB) 2006-07-27 US disclosed
WO-2005111080-A2 METHODS FOR REDUCING BIOFILM FORMATION IN INFECTIOUS BACTERIA HAPTOGEN LTD (GB) 2005-11-24 WO disclosed
WO-2005094883-A2 METHODS FOR INDUCING AUTOLYSIS IN INFECTIOUS BACTERIA HAPTOGEN LTD (GB) 2005-10-13 WO disclosed
CN-1681531-A Methods of treating infectious bacterial diseases with antibodies against lactones or lactone-derived signal molecules HAPTOGEN LTD (GB) 2005-10-12 CN disclosed
EP-1528935-A1 METHODS FOR THE TREATMENT OF AN INFECTIOUS BACTERIAL DISEASE WITH AN ANTI-LACTONE OR LACTONE DERIVED SIGNAL MOLECULES ANTIBODY Haptogen Ltd (GB) 2005-05-11 EP disclosed
WO-2004014423-A1 METHODS FOR THE TREATMENT OF AN INFECTIOUS BACTERIAL DISEASE WITH AN ANTI-LACTONE OR LACTONE DERIVED SIGNAL MOLECULES ANTIBODY HAPTOGEN LTD (GB) 2004-02-19 WO disclosed